التفاصيل البيبلوغرافية
| العنوان: |
Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers. |
| المؤلفون: |
Nagalla, S1, Thomson, L2, Oppong, Y3, Bachman, B1, Chervoneva, I3, Kraft, WK3 |
| المصدر: |
CTS: Clinical & Translational Science. Jun2016, Vol. 9 Issue 3, p176-180. 5p. |
| مصطلحات موضوعية: |
*APIXABAN, *BLOOD coagulation, *PROTHROMBIN, *VITAMIN K, *RIVAROXABAN |
| مستخلص: |
It was hypothesized that the four-factor prothrombin complex concentrate (4F-PCC) Kcentra 25 unit/kg would reverse impairment of thrombin generation in healthy volunteers dosed with apixaban to steady state. In this randomized, two-period crossover, assessor-blinded trial, 12 healthy subjects received 5 mg apixaban every 12 h. Three h after the fifth dose, four-factor prothrombin complex concentrate (4F-PCC) 25 unit/kg or saline were infused. Serial blood samples were assessed for thrombin generation using PPP-reagent and PPP-reagent low, anti-Xa, PT, and PTT assays. Geometric mean ratio was calculated at 30 min postinfusion, and at 24, 48, and 72 h. Peak thrombin generation was 76% higher at 30 min postinfusion with 4F-PCC ( p = 0.025). The difference declined to 24% at 24 h and resolved by 48 h. Other thrombin generation parameters were also partially normalized. There was no difference between 4F-PCC and saline in anti-Xa assessment at 30 min or later time points. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder